TLDR
- Agenus stock trades at $4.87 as BOT+BAL studies gain ESMO 2026 attention
- Three Agenus trials will showcase cancer data across multiple tumor types
- BOT+BAL studies target colorectal cancer and advanced sarcoma treatment needs
- Agenus continues expanding its immuno-oncology pipeline with clinical programs
- New presentations strengthen focus on earlier cancer immunotherapy use
Agenus Inc. (AGEN) shares traded at $4.87, down 2.60%, as the company advanced its cancer immunotherapy pipeline. The biotechnology company announced three BOT+BAL study abstracts accepted for poster presentations at ESMO Congress 2026. The presentations will highlight progress across colorectal cancer and advanced sarcoma treatment programs.
Agenus Advances BOT+BAL Research Across Multiple Cancer Types
Agenus will present data from investigator-sponsored trials involving botensilimab and balstilimab at the European Society for Medical Oncology Congress. The event will take place from October 23 to 27, 2026, in Madrid, Spain. Additionally, the studies demonstrate continued clinical interest in the company’s immunotherapy combination.
The company’s research includes neoadjuvant colorectal cancer, refractory metastatic colorectal cancer, and advanced sarcoma settings. Therefore, the presentations will provide insights from different patient groups and treatment stages. The studies also expand independent clinical experience with BOT+BAL across challenging cancer types.
Botensilimab and balstilimab combine two immune-based approaches designed to strengthen anti-tumor responses. Furthermore, botensilimab targets CTLA-4 pathways while balstilimab blocks PD-1 interactions. Together, the combination aims to improve immune activity against tumors with limited treatment responses.
NEOASIS Study Highlights Earlier Colorectal Cancer Treatment Approach
Agenus will feature updated results from the NEOASIS study during the ESMO Congress. The study evaluates BOT+BAL in patients with mismatch repair-deficient colorectal cancer. Moreover, the research examines immunotherapy before surgery in earlier treatment settings.
The NEOASIS study focuses on a biologically distinct group from the MSS/pMMR population. However, the findings support broader research into moving immunotherapy earlier for colon cancer patients. Consequently, the data may provide additional understanding of immune-based treatment strategies.
The company noted that researchers continue evaluating BOT+BAL across different colorectal cancer populations. Besides NEOASIS, another study will examine refractory MSS/pMMR metastatic colorectal cancer. The multicenter AGEO study will present real-world data from heavily treated patients.
The AGEO presentation will include findings on BOT+BAL use in advanced metastatic colorectal cancer. Additionally, the study will provide clinical experience from multiple treatment centers. The presentation will appear as an ePoster during the colon cancer session.
Agenus Expands Clinical Evidence Through Real-World Cancer Data
A third ESMO presentation will examine BOT+BAL treatment in advanced sarcoma patients. The Spanish expanded access program will provide real-world findings from clinical use. Hence, the research will add further information about the combination’s potential in rare cancers.
Agenus developed botensilimab as an Fc-enhanced anti-CTLA-4 antibody to activate immune responses. The treatment approach focuses on stimulating T cells and reducing immune suppression inside tumors. The therapy aims to create longer-lasting immune memory responses.
Clinical trials have treated approximately 1,300 patients with botensilimab and balstilimab programs. The company has reported activity across nine metastatic, late-line cancer types. Moreover, ongoing studies continue exploring broader applications for the combination.
Balstilimab remains an important part of Agenus’ immunotherapy pipeline through its PD-1 targeting mechanism. The antibody blocks PD-1 interactions with PD-L1 and PD-L2 proteins. The treatment may support stronger immune system activity against cancer cells.
Agenus operates as an immuno-oncology company focused on developing cancer therapies. The company maintains research, manufacturing, and clinical development capabilities. Its pipeline includes antibody treatments, cell therapies, and immune-based technologies.
The upcoming ESMO presentations highlight the company’s continued focus on advancing cancer treatment research. Additionally, the studies provide new clinical information from different disease areas. Consequently, Agenus continues building evidence around BOT+BAL as a potential immunotherapy option.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
